Champions Oncology, Inc. (CSBR)
4.79
-0.02
(-0.42%)
USD |
NASDAQ |
Oct 15, 16:00
4.82
+0.03
(+0.63%)
After-Hours: 20:00
Champions Oncology Research and Development Expense (Quarterly) : 2.344M for July 31, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2026 | 2.344M |
| April 30, 2026 | 2.115M |
| January 31, 2026 | 2.271M |
| October 31, 2025 | 2.616M |
| July 31, 2025 | 2.082M |
| April 30, 2025 | 1.963M |
| January 31, 2025 | 1.719M |
| October 31, 2024 | 1.689M |
| July 31, 2024 | 1.454M |
| April 30, 2024 | 2.049M |
| January 31, 2024 | 2.186M |
| October 31, 2023 | 2.515M |
| July 31, 2023 | 2.793M |
| April 30, 2023 | 2.852M |
| January 31, 2023 | 3.202M |
| October 31, 2022 | 2.604M |
| July 31, 2022 | 2.887M |
| April 30, 2022 | 2.59M |
| January 31, 2022 | 2.181M |
| October 31, 2021 | 2.299M |
| July 31, 2021 | 2.304M |
| April 30, 2021 | 2.07M |
| January 31, 2021 | 1.879M |
| October 31, 2020 | 1.65M |
| July 31, 2020 | 1.597M |
| Date | Value |
|---|---|
| April 30, 2020 | 1.819M |
| January 31, 2020 | 1.391M |
| October 31, 2019 | 1.341M |
| July 31, 2019 | 1.303M |
| April 30, 2019 | 1.248M |
| January 31, 2019 | 1.269M |
| October 31, 2018 | 1.193M |
| July 31, 2018 | 1.088M |
| April 30, 2018 | 1.094M |
| January 31, 2018 | 1.045M |
| October 31, 2017 | 1.115M |
| July 31, 2017 | 1.118M |
| April 30, 2017 | 1.076M |
| January 31, 2017 | 0.998M |
| October 31, 2016 | 1.008M |
| July 31, 2016 | 1.211M |
| April 30, 2016 | 1.176M |
| January 31, 2016 | 0.999M |
| October 31, 2015 | 0.919M |
| July 31, 2015 | 1.10M |
| April 30, 2015 | 1.088M |
| January 31, 2015 | 1.093M |
| October 31, 2014 | 1.249M |
| July 31, 2014 | 1.423M |
| April 30, 2014 | 0.651M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Medpace Holdings, Inc. | -- |
| Avantor, Inc. | -- |
| Personalis, Inc. | 16.34M |
| Adaptive Biotechnologies Corp. | 18.30M |
| 10X Genomics, Inc. | 56.79M |